Key Points
- Takeda insider Nicola Deidre Petal Greenway sold 12,980 shares for $235,067.80 at an average price of $18.11, reducing her position by 24.48% to 40,049 shares. She also sold 6,774 shares earlier in August.
- Takeda shares opened at $18.36, near their one-year high of $18.90, while the company recently exceeded quarterly expectations with $0.47 EPS and $7.50 billion in revenue.
- Analyst sentiment remains mixed, with ratings ranging from buy to sell and an overall “Hold” consensus; institutional investors own 9.17% of the stock.
Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Nicola Deidre Petal Greenway sold 12,980 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total value of $235,067.80. Following the transaction, the insider owned 40,049 shares in the company, valued at approximately $725,287.39. This trade represents a 24.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Nicola Deidre Petal Greenway also recently made the following trade(s):
- On Monday, August 10th, Nicola Deidre Petal Greenway sold 6,774 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total value of $115,835.40.
Takeda Pharmaceutical Stock Performance
Shares of NYSE TAK opened at $18.36 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The stock's fifty day moving average price is $16.70 and its two-hundred day moving average price is $17.17. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The firm has a market cap of $58.84 billion, a price-to-earnings ratio of 54.01 and a beta of -0.08.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.30. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $7.50 billion for the quarter, compared to analysts' expectations of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, equities analysts forecast that Takeda Pharmaceutical Co. will post 1.5 EPS for the current year.
Hedge Funds Weigh In On Takeda Pharmaceutical
Several hedge funds and other institutional investors have recently made changes to their positions in TAK. Valeo Financial Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 6.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company's stock worth $175,000 after acquiring an additional 632 shares during the period. Franklin Resources Inc. lifted its stake in Takeda Pharmaceutical by 3.8% during the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company's stock worth $285,000 after purchasing an additional 713 shares during the last quarter. Abel Hall LLC boosted its holdings in shares of Takeda Pharmaceutical by 2.3% in the 1st quarter. Abel Hall LLC now owns 34,099 shares of the company's stock valued at $632,000 after purchasing an additional 781 shares in the last quarter. Private Trust Co. NA boosted its holdings in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company's stock valued at $27,000 after purchasing an additional 783 shares in the last quarter. Finally, Checchi Capital Advisers LLC increased its stake in shares of Takeda Pharmaceutical by 5.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company's stock valued at $270,000 after purchasing an additional 786 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have recently commented on TAK. Weiss Ratings cut shares of Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, July 30th. Zacks Research raised Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a report on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold".
Check Out Our Latest Stock Analysis on Takeda Pharmaceutical
Takeda Pharmaceutical Company Profile
(
Get Free Report)
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
